Tuberculosis, pulmonary cavitation, and matrix metalloproteinases.
Catherine W M Ong, Paul T Elkington, Jon S Friedland
https://pubmed.ncbi.nlm.nih.gov/24713029/Actively Recruiting
Led by National University Hospital, Singapore · Updated on 2026-06-01
200
Participants Needed
6
Research Sites
4 weeks
Total Duration
Tuberculosis affecting the central nervous system CNS-TB remains a serious condition with high death rates and severe neurological problems despite current standard treatments. Researchers are studying whether adding doxycycline, a drug that may reduce harmful enzymes contributing to tissue damage, to standard anti-tuberculous therapy and corticosteroids can improve survival and reduce brain injury in CNS-TB patients. This is a Phase 2 randomized controlled trial focusing on outcomes at 8 weeks. Participants receive either doxycycline twice daily or a placebo, along with daily standard anti-tuberculosis drugs and corticosteroids tapered over 8 weeks. The anti-tuberculosis regimen includes multiple agents like rifampicin, isoniazid, ethambutol, and possibly others, adjusted for kidney function if needed. After 8 weeks, doxycycline or placebo is stopped, and patients continue their usual TB treatment under their physicians guidance. During the study, participants will have brain imaging and lumbar puncture at baseline and 8 weeks, with lab tests to measure specific enzymes and gene activity related to inflammation. Safety is monitored through liver tests and adverse event tracking. The main outcome is death or severe neurological disability measured by a standardized scale at 8 weeks. The study duration per participant is 8 weeks with close monitoring throughout.
CONDITIONS
Adjunctive Doxycycline for Central Nervous System Tuberculosis
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National University Hospital, Singapore
Lead Sponsor
National Medical Research Council (NMRC), Singapore
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Lumbar puncture and brain imaging required at baseline for enrolment
Duration - 8 weeks
Participants receive adjunctive doxycycline or placebo alongside standard anti-tuberculous treatment and corticosteroid therapy for CNS-TB.
Daily treatment with multiple drugs including doxycycline or placebo alongside corticosteroids and standard TB therapy for 8 weeks
Duration - Up to 8 weeks from randomization
Participants are monitored for mortality, neurological deficits, imaging changes, immune markers, and adverse events following treatment completion.
Assessments at 2 and 8 weeks including clinical visits and imaging
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Catherine W M Ong, Paul T Elkington, Jon S Friedland
https://pubmed.ncbi.nlm.nih.gov/24713029/Xuan Ying Poh, Jia Mei Hong, Chen Bai...
https://pubmed.ncbi.nlm.nih.gov/35073927/Qing Hao Miow, Andres F Vallejo, Yu Wang...
https://pubmed.ncbi.nlm.nih.gov/34128838/National University Hospital, Singapore
Lead Sponsor
National Medical Research Council (NMRC), Singapore
Collaborating Sponsor